IDH889

• CAT Number: I007263
• CAS Number: 1429179-07-6
• Molecular Formula: C23H25FN6O2
• Molecular Weight: 436.48
• Purity: ≥95%
• Synonyms: (4S)-3-[2-[[(1S)-1-[5-(4-fluoro-3-methylphenyl)pyrimidin-2-yl]ethyl]amino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one
• InChI: InChI=1S/C23H25FN6O2/c1-13(2)19-12-32-23(31)30(19)20-7-8-25-22(29-20)28-15(4)21-26-10-17(11-27-21)16-5-6-18(24)14(3)9-16/h5-11,13,15,19H,12H2,1-4H3,(H,25,28,29)/t15-,19+/m0/s1
• InChIKey: JDCYIMQAIKEACU-HNAYVOBHSA-N
• SMILES: CC1=C(C=CC(=C1)C2=CN=C(N=C2)[C@H](C)NC3=NC=CC(=N3)N4[C@H](COC4=O)C(C)C)F

IDH889（Cat No.:I007263）is an experimental inhibitor targeting mutant isocitrate dehydrogenase 2 (IDH2), an enzyme frequently altered in cancers such as acute myeloid leukemia (AML) and gliomas. Mutant IDH2 produces the oncometabolite 2-hydroxyglutarate (2-HG), which disrupts epigenetic regulation and drives tumorigenesis. By selectively blocking mutant IDH2 activity, IDH889 reduces 2-HG levels, restoring normal cellular differentiation and growth control. Preclinical studies highlighted its promise as a targeted therapy for IDH2-mutant cancers, making it part of ongoing efforts to develop precision oncology treatments aimed at metabolic vulnerabilities.